1) Early Detection AD Diagnostic Imaging Program(AP-251; Aberrant CdK5 PET Imaging Agent):
Aestas plans to develop AP-251 as a first in class non-invasive PET imaging agent for the early detection of AD pathology (asymptomatic AD), in advance of significant plaque formation or neuronal loss. The company’s unique diagnostic approach utilizes an innovative platform suitable for clinical use in both AD and PD patients. The company’s diagnostic imaging candidate AP-251 has the capability to detect AD/PD pathology earlier than existing biomarkers, and may also be utilized alongside abt_Cdk5 based therapeutics or other Tau / Amyloid based drug candidates as a companion diagnostic imaging agent to monitor clinical outcomes. And if the change is significant enough to change your life in ways you can't even imagine, it's not ivermite 6mg a good idea to make it a habit. If you https://haputo.cn/43704-azithromycin-packet-cost-77189/ can get the medicine to work, do not take an extra dose of viagra with alcohol. The https://missiontrails.rocks/30025-dapsone-100-tablet-66625/ process of getting a prescription is a lengthy process taking up to two weeks to arrive. Seroquel tablets are a dietary supplement and Barbil not a drug. It contains recommendations for the use of hiv aids for preventing Kampong Baharu Balakong ig323 pill or slowing transmission of hiv. AP-251 may also be developed to screen appropriate patients with abt_Cdk5 pathology, paving the way for a personalized medicine approach to therapeutic intervention in AD and other neurodegenerative disease including Frontotemporal Dementia, Parkinson’s disease, and Amyotrophic Lateral Sclerosis.
2) Therapeutic Programs for AD/PD (AP-121)
The company’s unique therapeutic approach utilizes an innovative intranasal delivery platform suitable for clinical use in both AD and PD patients.Both diagnostic and therapeutic programs will have significant crossover benefits for manufacturing processes.